medical management for patients with confirmed covid-19 · • see separate mis-c guideline •...
TRANSCRIPT
![Page 1: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/1.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
•
• •
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
![Page 2: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/2.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
![Page 3: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/3.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
•
•
•
•
•
•
•
•
•
•
•
•
•
![Page 4: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/4.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
![Page 5: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/5.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
![Page 6: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/6.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
•
•
![Page 7: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/7.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
![Page 8: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/8.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
https://www.fda.gov/media/141477/download
![Page 9: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/9.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.
![Page 10: Medical Management for patients with confirmed COVID-19 · • See separate MIS-C guideline • Additional therapies specific to COVID-19 (see subsequent guideline pages for detail)](https://reader034.vdocument.in/reader034/viewer/2022042713/5fa7dab3e35cf3364344f23f/html5/thumbnails/10.jpg)
Disclaimer: This guideline is designed for general use with most patients; each clinician should use his or her own independent judgment tomeet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.